Literature DB >> 27240926

Prenatal diagnosis of absent pulmonary valve syndrome from first trimester onwards: novel insights into pathophysiology, associated conditions and outcome.

I Gottschalk1, C Jehle2, U Herberg3, J Breuer3, K Brockmeier4, G Bennink4, A Hellmund2, B Strizek2, U Gembruch2, A Geipel2, C Berg1,2.   

Abstract

OBJECTIVE: To assess the spectrum of associated anomalies, intrauterine course and outcome in fetuses with absent pulmonary valve syndrome (APVS).
METHODS: All cases with a prenatal diagnosis of APVS at two centers over a period of 13 years were analyzed retrospectively. APVS was diagnosed in the presence of rudimentary or dysplastic pulmonary valve leaflets with to-and-fro blood flow in the pulmonary trunk on color and pulsed-wave Doppler ultrasound. Data on demographic characteristics, presence of associated conditions, Doppler studies and pregnancy outcome were reviewed.
RESULTS: During the study period, 40 cases of APVS were diagnosed prenatally. Thirty-seven (92.5%) cases were associated with tetralogy of Fallot (TOF) and three (7.5%) had an intact ventricular septum. Patency of the ductus arteriosus (DA) was found in 17/37 (45.9%) TOF cases and in all three cases with an intact ventricular septum. Mean gestational age at diagnosis was 19.7 (range, 12-34) weeks with 10 (25.0%) cases (all with TOF) diagnosed in the first trimester. TOF was an isolated finding in 15 (37.5%) cases. Chromosomal anomalies, cardiac defects and extracardiac anomalies were present in 18 (45.0%), four (10.0%) and three (7.5%) cases, respectively. Among the 40 cases, there were 19 (47.5%) terminations of pregnancy, six (15.0%) intrauterine deaths, four (10.0%) neonatal deaths and 11 (27.5%) survivors. Patency of the DA, reversed flow during atrial contraction in the ductus venosus, umbilical artery or fetal middle cerebral artery, and hydrops/increased nuchal translucency thickness were significantly associated with non-survival. All 10 cases diagnosed in the first trimester had a patent DA and abnormal Doppler parameters, eight had hydrops and/or increased nuchal translucency, six were associated with trisomy 13 or 18 and none survived.
CONCLUSION: APVS diagnosed in the first trimester is significantly associated with TOF, patency of the DA, abnormal Doppler parameters, lethal trisomies and intrauterine mortality. Cases of APVS with isolated TOF and agenesis of the DA have a better outcome than those with additional anomalies, with > 80% survival.
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  absent pulmonary valve syndrome; congenital heart defect; fetus; prenatal diagnosis; tetralogy of Fallot

Mesh:

Year:  2017        PMID: 27240926     DOI: 10.1002/uog.15977

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  4 in total

1.  Antenatal diagnosis of congenital heart disease by 3D ultrasonography using spatiotemporal image correlation with HDlive Flow and HDlive Flow silhouette rendering modes.

Authors:  André Souza Malho; Nathalie Jeanne Bravo-Valenzuela; Renato Ximenes; Alberto Borges Peixoto; Edward Araujo Júnior
Journal:  Ultrasonography       Date:  2022-01-14

2.  Prenatal Diagnosis, Associations and Outcome for Fetuses with Congenital Absence of the Pulmonary Valve Syndrome.

Authors:  Kadir Babaoğlu; Yasemin Doğan; Sevcan Erdem; Nazan Özbarlas; Eviç Başar; Orhan Uzun
Journal:  Anatol J Cardiol       Date:  2022-09       Impact factor: 1.475

3.  The multiform sonographic spectrum of arterial duct in right aortic arch.

Authors:  Enrico Chiappa; Cecilia Ridolfi; Adalgisa Cordisco
Journal:  Int J Cardiovasc Imaging       Date:  2021-07-08       Impact factor: 2.357

4.  Management and outcome of prenatal absent pulmonary valve syndrome.

Authors:  Florian Recker; Eva C Weber; Brigitte Strizek; Annegret Geipel; Christoph Berg; Ulrich Gembruch
Journal:  Arch Gynecol Obstet       Date:  2022-01-18       Impact factor: 2.493

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.